miR-218-5p Regulates Microglia-mediated Neuroinflammation through Type I Interferon Response in Parkinson’s Disease
Objective: To explore the effect of miR-218-5p on microglia activation and dopaminergic neurons damage in mice model of Parkinson's disease(PD) and its potential mechanisms. Background:…DUtch PARkinson Cohort (DUPARC): Contrast Sensitivity and Retinal Changes in Early Parkinson’s Disease Patients
Objective: To identify and characterize the correlation between static contrast sensitivity (SCS), dynamic contrast sensitivity (DCS), and thickness of the internal plexiform layer (IPL) in…CCL5 promotes Th17 migrating into SNpc by promoting Th17 proportion increase and LFA-1 expression
Objective: To explore the specific pathway by which CCL5 induces Th17 cells migrating into substantia nigra pars compacta (SNpc) to aggravate Parkinson's disease (PD). Background:…Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice
Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…PP1α negatively regulates D2 receptor mediated cadmium induced motor dysfunctions: protective potential of Quercetin.
Objective: The present study has been focused to identify the molecular targets that involved in Cadmium-induced motor dysfunctions. At the same time, we also focused…Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling
Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in enriched iPSC-derived human midbrain dopaminergic neurons
Objective: Develop and adapt a differentiation paradigm to produce enriched hiPSC-derived midbrain dopaminergic neurons (mDA), to resolve the temporal sequence of pathophysiological events in synucleinopathies.…Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease
Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD. Background: Study of the biochemical aspects…Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs
Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 15
- Next Page »